About: Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
Creator	Corti, Davide Lanzavecchia, Antonio Chen, Man Kong, Wing-Pui Chuang, Gwo-Yu Silacci, Chiara Ko, Kiyoon Sastry, Mallika Zhang, Baoshan Taylor, Geraldine Mascola, John Kumar, Azad Thom, Michelle Gordon, M Graham, Barney Kwong, Peter Salazar, Andres
Source	PMC
abstract	Appropriate adjuvant selection may be essential to optimize the potency and to tailor the immune response of subunit vaccines. To induce protective responses against respiratory syncytial virus (RSV)—a highly prevalent childhood pathogen without a licensed vaccine—we previously engineered a pre-fusion-stabilized trimeric RSV F (pre-F) “DS-Cav1” immunogen, which induced high titer RSV-neutralizing antibodies, in mice and non-human primates, when formulated with adjuvants Poly (I:C) and Poly (IC:LC), respectively. To assess the impact of different adjuvants, here we formulated RSV F DS-Cav1 with multiple adjuvants and assessed immune responses. Very high RSV-neutralizing antibody responses (19,006 EC(50)) were observed in naïve mice immunized with 2 doses of DS-Cav1 adjuvanted with Sigma adjuvant system (SAS), an oil-in-water adjuvant, plus Carbopol; high responses (3658–7108) were observed with DS-Cav1 adjuvanted with Alum, SAS alone, Adjuplex, Poly (I:C) and Poly (IC:LC); and moderate responses (1251–2129) were observed with DS-Cav1 adjuvanted with the TLR4 agonist MPLA, Alum plus MPLA or AddaVax. In contrast, DS-Cav1 without adjuvant induced low-level responses (6). A balanced IgG1 and IgG2a (Th2/Th1) immune response was elicited in most of the high to very high response groups (all but Alum and Adjuplex). We also tested the immune response induced by DS-Cav1 in elderly mice with pre-existing DS-Cav1 immunity; we observed that DS-Cav1 adjuvanted with SAS plus Carbopol boosted the response 2-3-fold, whereas DS-Cav1 adjuvanted with alum boosted the response 5-fold. Finally, we tested whether a mixture of ISA 71 VG and Carbopol would enhanced the antibody response in DS-Cav1 immunized calves. While pre-F-stabilized bovine RSV F induced very high titers in mice when adjuvanted with SAS plus Carbopol, the addition of Carbopol to ISA 71 VG did not enhance immune responses in calves. The vaccine response to pre-F-stabilized RSV F is augmented by adjuvant, but the degree of adjuvant-induced enhancement appears to be both context-dependent and species-specific.
has issue date	2017-10-26(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0186854
bibo:pmid	29073183
has license	cc0
sha1sum (hex)	0a05a7b95ce42f0b53c86a24842ecc9845a7d023
schema:url	https://doi.org/10.1371/journal.pone.0186854
resource representing a document's title	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
has PubMed Central identifier	PMC5658087
has PubMed identifier	29073183
schema:publication	PLoS One
resource representing a document's body	covid:0a05a7b95ce42f0b53c86a24842ecc9845a7d023#body_text
is schema:about of	named entity 'IMMUNOGEN' named entity 'AGONIST' named entity 'CHILDHOOD' named entity 'BUT' named entity 'ENGINEERED' named entity 'ASSESS' named entity 'POTENCY' named entity 'OBSERVED' named entity 'CALVES' named entity 'HERE' named entity 'TITER' named entity 'CAV1' named entity 'IMMUNIZED' named entity 'MPLA' named entity 'PRE' named entity 'PRIMATES' named entity 'IGG1' named entity 'RSV' named entity 'HTTPS' named entity '2-3' named entity 'STABILIZED' named entity 'ENHANCE' named entity 'OPTIMIZE' named entity 'SUBUNIT VACCINES' named entity 'MULTIPLE' named entity 'NEUTRALIZING ANTIBODY' named entity 'APPROPRIATE' named entity 'fold' named entity 'assessed' named entity 'agonist' named entity 'adjuvanted' named entity 'Poly' named entity 'immunity' named entity 'Th2' named entity 'vaccine' named entity 'fusion' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'TLR4' named entity 'ADDITION' named entity 'IGG2A' named entity 'DOSES' named entity 'NEUTRALIZING ANTIBODIES' named entity 'SYSTEM' named entity 'MAY BE' named entity 'OIL' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity '28I' named entity 'BALANCED' named entity 'ISA' named entity 'MODERATE' named entity 'CARBOPOL' named entity 'IMMUNE RESPONSE' named entity 'PREVIOUSLY' named entity 'ENHANCED' named entity 'PATHOGEN' named entity 'RESPONSES' named entity 'MIXTURE' named entity 'DIFFERENT' named entity 'AUGMENTED' named entity 'SELECTION' named entity 'RESPONSE TO' named entity 'ADJUVANTS' named entity 'CAV1' named entity 'GLYCOPROTEIN' named entity 'FUSION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software